Innovation

Defining physiological functions of syndecan-1 in health and disease using the syndecan-1 null mice

Children's Hospital Boston
posted on 03/18/2010

Cell surface heparan sulfate proteoglycans (HSPG) bind to a wide variety of bioactive molecules and regulate a wide variety of biological activities, including developmental processes, angiogenesis, blood coagulation, tumour metastasis, infection, and inflammation. Syndecan-1 is the major epithelial cell membrane HSPG in mammals. Dr. Pyong Park, PhD, from the Department of Respiratory Diseases, has developed a knock-out mouse by homologous recombination (mutation of exon 1 in a c57BL6 background) to study the physiological functions of syndecan-1 in health and in disease. Despite the variety of functional interactions that have been reported for syndecan-1 in cultured cells, Sdc1–/– mice are ostensibly normal and fertile. Dr. Park has shown that newborn mice deficient in syndecan-1 resist P. aeruginosa lung infection but become susceptible when given purified syndecan-1 ectodomains or heparin, but not when given ectodomain core protein, indicating that the ectodomain's heparan sulphate chains are the effectors. In wild-type newborn mice, inhibition of syndecan-1 shedding or inactivation of the shed ectodomain's heparan sulphate chains prevents lung infection. He also found that a pathogenetic mechanism in which a host response to tissue injury, syndecan-1 shedding, is exploited to enhance microbial virulence apparently by modulating host defenses. Additional work with the syndecan-1 knockout mice in tumorigenesis provided both genetic and biochemical evidence that syndecan-1 can modulate Wnt signalling, and is critical for Wnt-1–induced tumorigenesis of the mouse mammary gland. Further, recent studies indicate that syndecan-1 assures the correct functioning of inflammation by attenuating pro-inflammatory factors and facilitating the resolution of inflammation in a heparan sulfate-dependent manner.


Innovation Details
 

File Number: CMCC 1894 

Other Information: *Investigator(s)*
Pyong Woo Park

*Contact*
Maude Tessier, Maude.Tessier@childrens.harvard.edu


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact David Altman at Children's Hospital Boston for more information.

Request more info via email request more info
People

Case Manager:

David Altman David Altman

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

7,868 members 17,196 innovations 152 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...